A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

• Diagnosis of CD established at least 12 weeks before screening including bothendoscopic evidence and a histopathology report consistent with a diagnosis of CD

• Moderately to severely active CD based on CDAI criteria, defined as baseline (WeekI-0) CDAI score >=220 but <=450 and either mean daily SF count >=4, or mean daily APscore >=2

• Moderately to severely active CD based on SES-CD criteria assessed by baseline (WeekI-0) endoscopic evidence of active ileal and/or colonic CD as assessed duringcentral review of the screening video ileocolonoscopy defined as a SES-CD >= 6 forparticipants with colonic or ileocolonic disease, and SES-CD >= 4 for participantswith isolated ileal disease, based on the presence of ulceration in any 1 of the 5ileocolonic segments

• A female participant of childbearing potential must have a negative highly sensitiveserum pregnancy test (beta-hCG) at screening and a negative urine pregnancy test atWeek I-0 prior to administration of study intervention and agree to furtherpregnancy tests

• Demonstrated an inadequate response to, or failure to tolerate conventional therapybut naïve to advanced therapies (advanced drug therapy [ADT]-naïve) or inadequateresponse to (that is, primary or secondary nonresponse) or failure to tolerateadvanced therapy defined as biologics and/or advanced oral agents for the treatmentof CD- (ADT-inadequate responder [IR]) as defined in the protocol

Exclusion criteria:

• Has complications of CD, such as symptomatic strictures or stenoses, short gutsyndrome, or any other manifestation, that may require surgery while enrolled in thestudy and/or could impair the use of instruments (such as CDAI) to assess responseto study intervention

• Presence of a stoma or ostomy

• Participants with presence of active fistulas may be included if there is no surgeryneeded

• Colonic resection within 24 weeks before baseline or any other major surgeryperformed within 12 weeks before baseline

• Presence on screening colonoscopy of adenomatous colon polyps outside of an area ofknown colitis not removed before randomization